← Eichor
Study identifier: NCT05081401 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)

Condition: Multidrug Resistant Tuberculosis · Rifampicin Resistant Tuberculosis · Pre-XDR-TB  ·  Sponsor: Huashan Hospital

PhasePhase 3
Planned participants1050
Who can joinAll sexes, 16 Years to 75 Years
Healthy volunteersNo

About this study

The INSPIRE-TB study is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate the efficacy and safety of seven 9-month oral regimens compared to a 9-month standard of care (SOC) regimen in RR-TB participants susceptible to fluoroquinolones, and a bedaquiline-containing 9-month oral regimen compared to a 20-month conventional regimen in RR-TB participants resistant to fluoroquinolones

This description comes directly from the study's public registry record.

Talk to the study team

Feng Sun, Dr.  ·  (086)15921403893  ·  feng.sun@nmcid.org.cn

Yang Li, Dr.  ·  (086)18817583793  ·  lalaliy@sina.com

Always discuss trial participation with your own doctor first.

Locations (5)

Guiyang Public Health Treatment CenterGuiyang, Guizhou, ChinaRecruiting
People's Hospital of QiandongnanKaili, Guizhou, ChinaRecruiting
The Third People's Hospital of LiupanshuiLiupanshui, Guizhou, ChinaRecruiting
Affiliated Hospital of Zunyi Medical UniversityZunyi, Guizhou, ChinaRecruiting
Huashan Hospital of Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05081401